Delhi High Court allows Dr. Reddy's to manufacture semaglutide
after close1 source ↓written by the desknot a recommendation
- patent expires
- 20 Mar 2026
The Delhi High Court denied Novo Nordisk an interim injunction against Dr. Reddy's Laboratories and OneSource Specialty Pharma regarding semaglutide, crucial for its drugs Ozempic and Wegovy. The court found Novo failed to prove a prima facie case of patent infringement. The companies can export semaglutide until Novo's patent expires on 20 Mar 2026. 📦
This ruling may boost Dr. Reddy's market position in the global anti-diabetic sector, while Novo Nordisk's competitive edge could be challenged. 💊
Not investment advice. For informational purposes only.